Apellis Crashes As Safety Issues Outweigh Massive Eye-Drug Sales Beat

Apellis reports increased sales for Syfovre, but stock crashes as safety issues with the drug continue.

We believe that you are using automated tools to browse this website.

It may be caused by the following:

They prevent them from loading.

Reference ID: #8e4ef4b5-3726-11ee-8b70-6844726d7477

Report a problem


Cancel Send

We appreciate your feedback